Protecting Against AI’s Existential Threat
By Ilya Sutskever and Dario Amodei,
Wall Street Journal
| 10. 18. 2017
How to avoid the nightmare scenario of artificial intelligence? According to researchers from Elon Musk’s OpenAI, the trick is teaching machines to keep our interests in mind
On July 8, 2017, an AI system built by our research company, OpenAI, beat a semipro human player in solo matches of a battle arena video game called Dota 2. One month later, the same AI system beat a professional gamer ranked in the top 50. Three days after that it defeated the No. 1 solo Dota 2 player in the world. And it kept getting better: The Aug. 11 version of our AI beat the Aug. 10 version 60% of the time. Our AI learned to trick its opponents, predict what it couldn’t see and decide when to fight and when to flee.
Keeping a Careful Eye on AI
How do you create AI that doesn’t pose a threat to humanity? By teaching it to work with humans. Open AI collaborated with DeepMind, Google’s AI division, to design a training method that incorporates regular human feedback. The idea is to “humanize” AI...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...